Numerous agents are available for anticoagulation during percutaneous coronary intervention (PCI), and various antiplatelet agents are also used. With all of the medications available, an assessment must be made regarding the ischemic risk and risk of bleeding for an individual patient during elective PCI when selecting the optimal medical strategy to support PCI. Whether new antiplatelet medications will enhance or reduce complications when paired with various newer anticoagulant agents requires further investigation. This article summarizes existing data examining the benefits and limitations of the various anticoagulant and antiplatelet medications, and summarizes guidelines for their use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.iccl.2013.06.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!